GGrantIndex
← Search

A PHASE I SAFETY AND IMMUNOGENICITY TRIAL OF AN ALPHAVIRUS REPLICON HIV SUBTY...

$68,763M01FY2004RRNIH

Vanderbilt University, Nashville TN

Investigators

Linked publications & trials

View original record on NIH RePORTER →